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Purpose: Comparisons of rhythm and rate control strategies for stroke prevention in patients with atrial fibrillation (AF) are still 
inconclusive. We compared differences in clinical outcomes between the rhythm and rate control strategies.
Materials and Methods: The COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation 
(CODE-AF) registry prospectively enrolled 6000 patients who were treated for AF using real-world guideline adherence at multi-
ple referral centers. In total, 2508 (41.8%) patients were clinically followed up for over six months. Of these, 1134 (45.2 %) patients 
treated by rhythm control and 1374 (54.8 %) patients treated by rate control were analyzed for clinical outcomes, including stroke 
and cardiovascular outcomes.
Results: Among all patients (age, 68±10 years; male, 62.4%), those treated with the rhythm control strategy were significantly 
younger, had more symptomatic paroxysmal AF, and a shorter AF duration, and were less likely to have diabetes, renal dysfunc-
tion, and heart failure, compared to those treated with the rate control strategy (CHA2DS2-VASc score 2.4±1.5 vs. 3.1±1.7, p<0.001). 
Even though oral anticoagulation was similarly prescribed in both groups, occurrence of stroke was less likely to occur in the 
rhythm control strategy group (0.0% vs. 0.7%, p=0.015). Multivariate Cox hazard regression showed that only age, especially more 
than 75 years old, were significantly correlated with the occurrence of stroke, regardless of the strategy used for treatment.
Conclusion: In this prospective AF cohort, compared with the rate control strategy, the rhythm control strategy was associated 
with fewer cardiovascular events and strokes in a short-term period.
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INTRODUCTION
Atrial fibrillation (AF) is the most common sustained arrhyth-
mia, which reduces the quality of life, and is mainly associated 
with the major complication of stroke.1,2 Current practical guide-
lines recommend a risk-stratified approach using only oral 
anticoagulation treatment (OAC) based on CHA2DS2-VASc scores 
for the prevention of stroke occurrence.2,3 In a meta-analysis, 
warfarin significantly reduced the risk of stroke occurrence,4-6 
and a new OAC had an additional significant benefit of reduc-
ing stroke occurrence, compared with warfarin.6 However, 
principally, a restored and maintained sinus rhythm with re-
duced AF burden is expected to reduce the risk of stroke and 
to offer good prognosis.7 Nevertheless, the superiority of rhythm 
control over the rate control strategy for AF management has 
not been proven as having a preventive effect for the occur-
rence of stroke.8-11 A few studies have shown that the rhythm con-
trol strategy is associated with favorable outcomes and a signifi-
cantly lower risk of stroke12,13 beyond symptomatic care in AF 
treatment. Therefore, we investigated whether the rhythm con-
trol strategy prevents the occurrence of stroke and has more 
favorable outcomes, compared with the rate control strategy, 
in patients with AF in a prospective national cohort that ad-
hered to current guidelines. 
MATERIALS AND METHODS
Study design and enrolled patients
The COmparison study of Drugs for symptom control and 
complication prEvention of Atrial Fibrillation (CODE-AF) is a 
prospective, multicenter, observational study performed at 10 
tertiary centers that encompass all geographical regions of Ko-
rea. The aim of the CODE-AF registry is to describe the clinical 
epidemiology of patients with AF and to determine the diag-
nostic and therapeutic processes (including the organization 
of programs for AF management) applied to these patients and 
their clinical outcomes. The registry was designed and coordi-
nated by the Korea Heart Rhythm Society, which provides sup-
port to related committees, national coordinators, and partici-
pating centers. Data are entered into a common electronic 
database that limits inconsistencies and errors and provides 
online help for key variables. Each center can see its own data 
and data from all other participating centers. The study was 
approved by the ethics committee of each center (EMC 2016-
05-003), and all patients provided informed consent for their 
inclusion. This study was registered at ClinicalTrials.gov 
(NCT02786095).
From June 2016 to April 2017, each center started to pro-
spectively enroll 6000 patients with nonvalvular AF who were 
>18 years of age, attended an outpatient clinic, and were hos-
pitalized on the same day for AF. Of these, 2508 (41.8%) patients 
were clinically followed up for over six months (Supplementary 
Fig. 1, only online). Finally, the CODE-AF enrolled patients 
who were clinically followed up consisted of 1134 (45.2%) pa-
tients treated with the rhythm control strategy and 1374 (54.8%) 
patients treated with the rate control strategy.
The CHA2DS2-VASc and Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile in-
ternational normalized ratio, Elderly, Drugs/alcohol concom-
itantly (HAS-BLED) scores were calculated for all patients with 
nonvalvular AF. Chronic kidney disease was defined as a glo-
merular filtration rate less than 60 mL/min/1.73 m2 according 
to the Chronic Kidney Disease Epidemiology Collaboration.14
Oral anticoagulation strategy
According to the 2016 European Society of Cardiology and 
2014 American Heart Association/American College of Cardi-
ology/Heart Rhythm Society guidelines for patients with AF,2,15 
AF patients without clinical stroke risk factors are not to un-
dergo antithrombotic therapy, whereas patients with stroke 
risk factors (i.e., a CHA2DS2-VASc score of 1 and 2 for men and 
women, respectively) are recommended to be prescribed OAC. 
Rhythm and rate control strategies
For the rate-control strategy of AF treatment, beta-blockers, 
digoxin and diltiazem, or verapamil were selected to control 
the heart rate in patients with AF. For the rhythm control strat-
egy of AF treatment, dronedarone, flecainide, propafenone, so-
talol, and amiodarone were selected to maintain the sinus 
rhythm according to structure heart disease. For active rhythm 
control, electrical cardioversion and catheter ablation were con-
sidered in selected patients2,3,16,17 at each center.
Clinical outcome
A follow-up visit was scheduled every 6 months, and a personal 
interview by phone was planned for those who could not make 
the follow-up visit, although no actual phone interviews were 
conducted during the study. We assessed the following out-
comes at follow up: 1) all-cause death, 2) hospitalization, 3) 
myocardial infarction, 4) stroke, systemic embolization, or tran-
sient ischemic attack, and 5) bleeding.
Definition of bleeding
Major bleeding was defined as fatal bleeding, symptomatic 
bleeding in a critical area or organ, and bleeding causing a de-
cline in hemoglobin level of 20 g/L or more or leading to trans-
fusion of two or more units of whole blood or red cell.18 Non-
major bleeding was defined as any sign or symptom of hemorr-
hage, including bleeding found by imaging alone, which does 
not fit the criteria for major bleeding.19
Statistical analysis
 Continuous variables are expressed as means±standard devi-
ations, and categorical variables are reported as frequencies 
(percentage). Multivariable Cox regression hazard models were 
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constructed to assess the independent relationship of stroke 
and clinical outcomes adjusting for demographic variables. 
Statistical analyses were performed using SPSS ver. 20.0 (IBM 
Corp., Armonk, NY, USA) and MedCalc (MedCalc software, 
version 12.3, Acacialaan, Ostend, Belgium). A p value <0.05 
was considered statistically significant. 
RESULTS
Baseline characteristics
AF patients treated with the rhythm control strategy were 
younger than those treated with the rate control strategy (65± 
10 vs. 70±10, p<0.001), and the proportions of men were 64.9% 
and 60.1%, respectively.
AF patients treated with the rhythm control strategy more 
frequently had hypertension, symptomatic paroxysmal AF, a 
shorter duration, electrical external cardioversion, and expe-
rienced catheter ablation, compared to those treated with the 
rate control strategy. However, AF patients treated with the 
rate control strategy more frequently had diabetes, dyslipid-
emia, chronic kidney disease, heart failure, and a larger left 
atrium size than those treated with the rhythm control strategy. 
The CHA2DS2-VASc score for patients treated with the rhythm 
control strategy was lower than in those treated with the rate 
control strategy (2.4±1.5 vs. 3.1±1.7, p<0.001) (Table 1). 
Oral antithrombotic agents and rate and rhythm control
The majority of patients were treated with one or more anti-
thrombotic agents. Warfarin and a new OAC (17.3% vs. 57.8%) 
were the most prescribed antithrombotic agents, followed by 
an anti-platelet agent, all of which were similarly prescribed in 
both groups (Supplementary Table 1, only online). In the rate 
control strategy group, beta-blockers were the most commonly 
Table 1. Comparison of the Baseline Characteristics of Patients Treated with the Rhythm and the Rate Control Strategy 
Variables All (n=2508) Rhythm control (n=1134) Rate control (n=1374) p value
Age (yr)   68±10   65±10   70±10 <0.001*
Male, n (%) 1564 (62.4)   737 (64.9)   827 (60.1)   0.013*
BMI (kg/m2) 24.6±3.4 24.7±3.1 24.6±3.6   0.728
Hypertension, n (%) 1564 (62.4)   737 (64.9)   827 (60.1)   0.001*
Diabetes mellitus, n (%)   682 (27.2)   265 (23.3)   417 (30.3)   0.001*
Dyslipidemia, n (%)   855 (34.1)   362 (31.9)   493 (35.8)   0.033*
Previous MI, n (%)   91 (3.6)   35 (3.0)   56 (4.0)   0.276
Previous HF, n (%)   313 (12.5) 110 (9.7)   203 (14.7) <0.001*
Previous CKD, n (%)   251 (10.0)   78 (6.8)   173 (12.5) <0.001*
Previous ICD, n (%)   30 (1.2)   10 (0.8)   20 (1.4)   0.277
Previous PPM, n (%) 168 (6.7)   73 (6.4)   95 (6.9)   0.634
Previous cancer, n (%)   256 (10.2) 102 (8.9)   154 (11.2)   0.068
Previous stroke, n (%)   451 (18.0)   188 (16.5)   263 (19.1)   0.163
Previous ECV, n (%)   523 (20.9)   253 (22.3)   270 (19.6)   0.119
Previous AFCA, n (%)   510 (20.3)   273 (24.0)   237 (17.2) <0.001*
CHA2DS2-VASc score   2.8±1.6   2.4±1.5   3.1±1.7 <0.001*
HAS-BLED score   1.8±1.0   1.6±0.9   1.9±1.0 <0.001*
Systolic BP (mm Hg) 120±15 121±14 120±15   0.200
Diastolic BP (mm Hg)   73±11   72±10   73±11   0.200
Heart rate (bpm)   74±15   71±14   77±15   0.001*
LA size (mm) 43±8 41±7 45±8   0.001*
Ejection fraction (%) 60±9 61±7   59±10   0.001*
Baseline AF, n (%)   465 (55.4)   272 (23.9)   193 (13.0)   0.001*
AF duration <48 hrs, n (%)   493 (19.7)   268 (23.6)   225 (16.3) <0.001*
Symptomatic AF, n (%) 1453 (57.9)   660 (58.2)   793 (57.7)   0.026*
AF type, n (%) <0.001*
Paroxysmal AF 1593 (63.5)   827 (72.9)   766 (55.7)
Persistent AF   770 (30.7)   291 (25.6)   479 (34.8)
Permanent AF 145 (5.8)   16 (1.4) 129 (9.3)
BMI, body mass index; MI, myocardial infarction; HF, heart failure; CKD, chronic kidney disease; ICD, intracardiac defibrillator; PPM, permanent pacemaker; ECV, 
electrical cardioversion; AFCA, atrial fibrillation catheter ablation; BP, blood pressure; LA, left atrium; AF, atrial fibrillation.
Data are presented as a mean±standard deviation or number (percentage).
*Statistically significant.
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prescribed medication, followed by non-hydropyridine calci-
um channel blockers and digoxin. In the rhythm control strat-
egy group, flecainide was the most commonly prescribed med-
ication, followed by amiodarone and propafenone (Table 2).
Comparison of clinical outcomes between the rate 
control and the rhythm control groups
The mean follow-up durations were 5.9±1.2 and 5.8±1.2 months 
in the rhythm control and the rate control groups, respectively. 
Significantly more patients treated with the rhythm control 
strategy maintained a sinus rhythm than those treated with 
the rate control strategy (73.2% vs. 31.6%). Clinical outcomes 
including hospitalization, myocardial infarction, and death and 
bleeding were similar between all patients treated with rhythm 
control and with rate control. However, the incidence of stroke 
in the rhythm control group was 0%, compared with 0.7% in 
the rate control group (p=0.015). 
In Cox regression analysis, although non-rhythm control 
was associated with a higher risk of stroke [hazard ratio (HR) 
9.04; 95% confidence interval (CI), 1.15−70.6] in univariate anal-
ysis, it was not associated with higher risk of stroke (HR 0.27; 
95% CI, 0.03−2.33) in the multivariate analysis.
DISCUSSION
Main findings
In our study with an AF prospective cohort, although non-
rhythm control was significantly associated with stroke in uni-
variate analysis, it was not significantly associated with stroke 
in multivariate analysis. 
Comparison of differences between the rate and the 
rhythm control strategies for cardiovascular mortality
Several trials have demonstrated that the rhythm control strate-
gy offers no benefit on cardiovascular mortality in patients 
with AF, compared with the rate control strategy, and two meta-
analyses reported overall risk ratios of 0.95 (95% CI 0.76−1.19) 
and 1.15 (95% CI 0.15−1.88).8,9,20-22 These negative results for 
the rhythm control strategy have been attributed to the ineffi-
ciency of the antiarrhythmic drugs to maintain a sinus rhythm 
and to the fact that the beneficial effects of antiarrhythmic drugs 
are offset by their adverse effects.7 Unlike previous designed 
rhythm control in AF treatment, our study showed that an ac-
tive rhythm control strategy that included electrical cardiover-
sion or catheter ablation applied to medically refractory AF pa-
tients or to patients with antiarrhythmic drug-related adverse 
Table 2. Comparison of Treatments in the Rhythm and the Rate Control Strategy Groups
Variables All (n=2508) Rhythm control (n=1134) Rate control (n=1374) p value
Warfarin, n (%)   434 (17.3)   185 (16.3) 249 (18.1)   0.233
Dabigatran, n (%)   374 (14.9)   180 (15.8) 194 (14.1)   0.219
Apixaban, n (%)   582 (23.2)   249 (21.9) 333 (24.2)   0.178
Ribaroxaban, n (%)   404 (16.1)   161 (14.1) 243 (17.6)   0.018*
Edoxaban, n (%)   90 (3.6)   33 (2.9) 57 (4.1)   0.097
Aspirin, n (%)   377 (15.0)   196 (17.2) 181 (13.1)   0.004*
Clopidogrel, n (%) 178 (7.2)   86 (7.5) 92 (6.6)   0.407
Statin, n (%)   944 (37.6)   406 (35.8) 538 (39.1)   0.084
ARB, n (%)   953 (37.9)   393 (34.6) 541 (39.3)   0.013*
Beta-blocker, n (%)   0.002*
Bisoprolol   612 (24.4)   273 (24.0) 339 (24.6)
Carvedilol   392 (15.6)   165 (14.5) 227 (16.5)
Metoprolol   11 (0.4)     6 (0.5)   5 (3.6)
Nebivolol 118 (4.7)   46 (4.0) 72 (5.2)
Propranolol   91 (3.6)   38 (3.3) 53 (3.8)
Atenolol 198 (7.9) 105 (9.2) 93 (6.7)
Non-hydropyridine CCB, n (%)   736 (29.3)   299 (26.3) 437 (31.8)   0.002*
Digoxin, n (%) 183 (7.3)   13 (1.1) 170 (12.3) <0.001*
Propafenone, n (%) 222 (8.9)   222 (19.5) 0
Flecainide, n (%)   579 (23.0)   579 (51.0) 0
Pilsicanide, n (%)   35 (1.3)   35 (3.0) 0
Dronedarone, n (%)   75 (3.0)   75 (6.6) 0
Amiodarone, n (%) 238 (9.4)   238 (20.9) 0
Sotalol, n (%)   23 (0.9)   23 (2.2) 0
ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
Data are presented as a mean±standard deviation or number (percentage).
*Statistically significant.
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events minimized the need for antiarrhythmic drugs and hence 
prevented antiarrhythmic toxicities. In real practice with guide-
line adherence,2,15,23 a physician considers the optimal choice 
among the use of antiarrhythmic drugs and catheter ablation 
to minimize risk and to maximize benefits in order to restore 
and maintain a sinus rhythm. However, in our study, even though 
the rhythm control strategy group was younger, had a smaller 
proportion of heart failures and chronic kidney diseases, and 
was significantly superior for maintaining a sinus rhythm at 
follow-up (73.2% vs. 31.6%, p<0.001), the rhythm control strat-
egy exhibited no benefit for cardiovascular mortality, com-
pared with the rate control strategy, over a short-term follow up 
duration, as has been previously reported.8,11,22
Comparison of differences between the rate and the 
rhythm control strategies for stroke
Two meta-analyses comparing the pharmacological rhythm 
and the rate control strategy reported that the incidence of st-
roke was found to be statistically similar between the two 
groups with an overall odds ratio of 0.99 (95% CI 0.75−1.30) 
and a risk ratio of 0.96 (95% CI 0.68−1.34).8,22 However, recent 
studies have demonstrated that the rhythm control strategy 
including catheter ablation was associated with lower rates of 
stroke among patients with AF.12,13,24 This reduced risk of stroke 
associated with an optimal rhythm control including catheter 
ablation was implicated to maintain a sinus rhythm and to re-
duce the burden of AF.1,12,25 In our study, patients with the rhythm 
control strategy showed a significantly lower risk of stroke, 
compared with those with the rate control strategy [1 (0%) vs. 
10 (0.7%), p=0.015], at the short-term follow-up duration (Table 
3). However, rhythm control group was associated with better 
prognosis due to better patient baseline characteristics in the 
rhythm control group (Tables 1 and 4).
OACs are the main contributor to the prevention of stroke.5,26 
Warfarin reduced stroke overall by 60% to 70%, and new OACs 
have a beneficial effect on additional significant reductions of 
overall 20% relative to warfarin.6 In our study, a new OAC was 
mostly used (71%) and similarly prescribed between the pa-
Table 3. Comparison of Clinical Outcomes for the Rhythm and the Rate Control Strategy Groups 
Variables All (n=2508) Rhythm control (n=1134) Rate control (n=1374) p value
Sinus rhythm at follow-up, n (%) 1266 (50.4) 831 (73.2) 435 (31.6) <0.001*
Stroke, n (%)   11 (0.4)   1 (0.0) 10 (0.7)   0.015*
Ischemic     4 (0.1)   0 (0.0)   4 (0.2)
Hemorrhagic     1 (0.0)   1 (0.0)   0 (0.0)
Uncertain classification     6 (0.2)   0 (0.0)   6 (0.4)
Transient Ischemic attack, n (%)     2 (0.0)   1 (0.0)   1 (0.7) 0.119
Systemic embolization, n (%)     2 (0.1)   0 (0.0)   2 (0.2) 0.198
All bleeding, n (%)   41 (1.6) 18 (1.5) 23 (1.6) 0.894
Major, n (%)     4 (0.1)   2 (0.1)   2 (0.1)
Myocardial infarction, n (%)     2 (0.1)   1 (0.0)   1 (0.0) 0.891
Death, n (%)   10 (0.4)   2 (0.1)   8 (0.5) 0.105
Hospitalization, n (%)     7 (0.3)   3 (0.2)   4 (0.3) 0.248
Data are presented as means±standard deviations or numbers (percentage).
*Statistically significant.
Table 4. Cox Regression Analyses for the Prediction of Stroke Occurrence
Variables
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.12 1.04–1.21 0.002* 1.06 0.97–1.17 0.170
Age ≥65 years 1.16 0.02–1.32 0.090 
Age ≥75 years 3.58 1.66–7.77 0.001*
Female 0.92 0.27–3.14 0.896 0.51 0.13–1.94 0.324
AF type† 3.08 1.33–7.11 0.008* 2.71 0.66–11.01 0.162
Non-rhythm control 9.04 1.15–70.6 0.035* 0.27 0.03–2.33 0.235
Heart failure 1.09 0.97–1.23 0.136 0.86 0.16–4.46 0.862
Hypertension 0.21 0.02–1.65 0.139 0.40 0.04–3.50 0.411
Diabetes mellitus 0.97 0.88–1.05 0.498 0.22 0.03–1.22 0.083
LA size (mm) 1.08 1.01–1.14 0.015* 1.03 0.97–1.11 0.188
CHA2DS2-VASc 1.01 0.99–1.04 0.142 1.53 0.92–2.54 0.101
HR, hazard ratio; CI, confidence interval; AF, atrial fibrillation; LA, left atrium.
*Statistically significant, †Paroxysmal type as the reference category.
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tients in the rhythm control group and those in the rate con-
trol group among the 73% OAC-indicated study patients.
In the J-Rhythm registry with Japanese patients,27 the inci-
dence rate of ischemic stroke was 13.4 per 1000 person-year. A 
previous stroke (HR 3.25), age ≥75 years (HR 2.31), and incr-
eased CHA2DS2-VASc score were considered as independent 
risk factors for ischemic stroke in the multivariate analysis.27 Si-
milar with other Western registries that compared the rhythm 
and the rate control strategy,25,28 patients treated with the 
rhythm control strategy were younger in age and had a small-
er proportion of underlying diseases and a lower CHADS2 or 
CHA2DS2-VASc score than those treated with the rate control 
strategy. In RECORDAF, significantly more patients in the 
rhythm control group had maintained a sinus rhythm than 
those in the rate control group (80% vs. 33%, p<0.001) and had 
a lower occurrence of stroke than those in the rate control 
group (1.7% vs. 2.8%, p=0.008) at the 1-year follow-up. How-
ever, in ORBIT-AF, the rhythm control group had a significantly 
smaller proportion of OACs than that of the rate control group 
(68% vs. 74%, p<0.001). However, the incidence of stroke was 
similar between the two groups [1.1% vs. 1.5%, adjusted HR 
0.87 (95% CI 0.66−1.16), p=0.345].
In our study, the incidence rate of stroke was 9.0 per 1000 
person-years as previously reported by J-Rhythm registry. Pa-
tients treated with the rhythm control strategy were younger 
and had less underlying cardiovascular disease and stroke 
risk factors, while those treated with the rate control strategy 
were older and had more stroke risk factors, including diabe-
tes, dyslipidemia, heart failure, and chronic kidney disease, and 
a higher CHA2DS2-VASc score. In addition, catheter ablation 
for anti-arrhythmic refractory AF rhythm control was more fre-
quently undertaken in our study, compared with other previ-
ous registries. However, the rhythm control strategy might not 
be attributed to lower stroke, compared with the rate control 
strategy, in the multivariate analysis until the CABNA results 
are available (Catheter Ablation vs. Anti-arrhythmic Drug 
Therapy for Atrial Fibrillation Trial) for stroke prevention.1,24 In 
our study, the patients with rhythm control that included cath-
eter ablation were younger, had a lower risk of stroke (mean of 
CHA2DS2-VASc score 2.8±1.6), and significantly more often 
maintained sinus rhythm at follow-up, compared with those 
treated with the rate control strategy. In the Kaplan-Meier 
curve (Fig. 1), patients treated with the rhythm control strate-
gy seemed to be significantly associated with a higher stroke-
free survival rate during over 6 months of follow up. However, 
in Cox regression multivariate analysis, only AF patients aged 
over 75 years was indicated as an independent risk factor for 
stroke occurrence (Table 4). We noted that 82% (9/11) of all 
stroke have occurred in the AF patients aged over 75 years and 
that the effect of rhythm control strategy could be offset by age. 
In addition, with the on-going CODE-AF trial, our data had 
only a short mean follow-up of 5.8 months, and a longer fol-
low-up duration is needed to assess the differences between 
rhythm and rate control strategies in stroke prevention.
Our study has several limitations. First, our study has short 
follow-up duration and unknown confounding factors. Sec-
ond, the data used for the analysis cannot quantify AF burden, 
which may have differed between the rhythm and the rate 
control strategy groups. Third, there are concerns for a suffi-
cient power of association for stroke occurrence in this study.
In conclusions, in this prospective AF cohort with guideline 
adherence, the rhythm control strategy showed no benefit on 
cardiovascular mortality, but seemed to lower the risk of st-
roke compared, to the rate control strategy. However, only 
age, especially older than 75 years, was deemed an indepen-
dent risk factor for the occurrence of stroke, regardless of which 
control strategy was applied.
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